Compare GE Vernova Inc (GEV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Vernova Inc vs Zimmer Biomet Holdings Inc — how do they compare? GE Vernova Inc trades at $1,003.76 (market cap $266.16B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: GE Vernova Inc is far larger — about 15.7× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (1.08%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| GEV | ZBH | |
|---|---|---|
Market Cap | $266.16B | $16.95B |
Volume | 2,324,165 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $1.17K | $103.98 |
52-Week Low | $547.96 | $79.58 |
Typical Hold Time | 36 Days | 89 Days |
Enterprise Value | $255.83B | $24.02B |
Dividend Yield | 0.2% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $1,007.77, up 1.07% with strong bullish technical momentum. The stock shows impressive fundamental growth with 2026 revenue projected at $41.4B and net profit margin expanding to 23.03%. Recent catalysts include securing the first US construction permit for its BWRX-300 small modular reactor and a $176B backlog. Analyst consensus remains strongly bullish with 22 buy ratings and a $1,270 price target, representing 26% upside potential from current levels.
The outlook remains positive given the company's positioning in AI-driven power infrastructure demand, though valuation multiples appear elevated with P/E at 28.65 and EV/EBITDA at 85.22. Key risks include execution challenges in the wind segment and competitive pressures in the nuclear energy space. The stock's recent 45% YTD gain suggests much optimism is already priced in, requiring continued strong execution to justify further upside.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Vernova Inc
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
